Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...
Your Compass In Indian Pharma
Key Highlights: Implications: This approval moves Enhertu + Perjeta into the front line of HER2‑positive metastatic breast cancer care in India, displacing taxane + tra...